SyntheX

SyntheX uses synthetic biology to create the next generation of drug discovery platforms. Using genetically engineered circuits, we rely on intracellular drug selection as opposed to in-vitro screening. This allows us to discover unbiased compounds with novel modes of action that can engage targets in either competitive or allosteric ways. We have developed ToRPPIDO to discover disruptors of protein-protein interactions (PPIs), and ToRNeDO to discover functional molecular glues for degraders of a neosubstrate of interest with a desired E3 ligase. In the same cells, we incorporate our proprietary DNA-encoded libraries of peptides and macrocycles to enable the production and selection of molecules in an efficient and high throughput manner. Our lead programs focus on oncology.

网站

http://www.SyntheXlabs.com

SyntheX的外部链接

所属行业

生物技术研究

规模

11-50 人

总部

San Francisco，California

类型

私人持股

创立

2016

领域

Oncology、Synthetic Lethality、Biotechnology、Synthetic Biology、Cancer Genetics、Therapeutics、Genetic engineering、Targeted protein degradation、Ras、Functional Selection、Drug discovery、Biologics、Peptides、Molecular glues和Raf